Investors Shareholders

About
Teams
Responsibility
Investments
Media

Current portfolio

Imcyse

Imcyse develops active specific immunotherapies for the treatment and prevention of severe chronic diseases

Sector
Healthcare
Country
Belgium
Fund
LSP 6
Entry
2019
Web
imcyse.com

Sector
Healthcare
Country
Belgium
Fund
LSP 6
Entry
2019
Web
imcyse.com

Latest from Imcyse

01 December 2022
EQT partners with Nobel Prize Outreach to inspire and engage global audiences on societal challenges
28 November 2022
EQT Infrastructure enters exclusive negotiations to acquire a majority stake in Trescal, a global leader in calibration laboratories
22 November 2022
EQT AB’s Nomination Committee for the Annual Shareholders’ Meeting 2023
22 November 2022
Karo Intressenter AB announces final outcome of the public cash offer to the shareholders in Karo Pharma Aktiebolag
09 November 2022
EQT Ventures III closes Europe's largest venture capital fund committed to early-stage tech startups

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of newsRegulatory NewsEQT News

Preferred languageEnglishSwedish

Email address

About

Teams

Responsibility

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180